全文获取类型
收费全文 | 3739篇 |
免费 | 94篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 100篇 |
妇产科学 | 175篇 |
基础医学 | 689篇 |
口腔科学 | 63篇 |
临床医学 | 412篇 |
内科学 | 461篇 |
皮肤病学 | 77篇 |
神经病学 | 100篇 |
特种医学 | 272篇 |
外科学 | 528篇 |
综合类 | 109篇 |
预防医学 | 284篇 |
眼科学 | 75篇 |
药学 | 289篇 |
中国医学 | 3篇 |
肿瘤学 | 183篇 |
出版年
2022年 | 41篇 |
2021年 | 52篇 |
2019年 | 31篇 |
2018年 | 33篇 |
2016年 | 42篇 |
2015年 | 44篇 |
2014年 | 59篇 |
2013年 | 60篇 |
2012年 | 99篇 |
2011年 | 146篇 |
2010年 | 100篇 |
2009年 | 72篇 |
2008年 | 123篇 |
2007年 | 139篇 |
2006年 | 135篇 |
2005年 | 126篇 |
2004年 | 110篇 |
2003年 | 92篇 |
2002年 | 73篇 |
2001年 | 79篇 |
2000年 | 104篇 |
1999年 | 85篇 |
1998年 | 65篇 |
1997年 | 49篇 |
1996年 | 38篇 |
1995年 | 33篇 |
1994年 | 34篇 |
1993年 | 32篇 |
1992年 | 72篇 |
1991年 | 110篇 |
1990年 | 117篇 |
1989年 | 125篇 |
1988年 | 113篇 |
1987年 | 144篇 |
1986年 | 115篇 |
1985年 | 100篇 |
1984年 | 71篇 |
1983年 | 56篇 |
1982年 | 35篇 |
1979年 | 48篇 |
1978年 | 29篇 |
1977年 | 38篇 |
1976年 | 45篇 |
1975年 | 51篇 |
1974年 | 69篇 |
1973年 | 51篇 |
1972年 | 48篇 |
1971年 | 40篇 |
1970年 | 45篇 |
1969年 | 34篇 |
排序方式: 共有3851条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.
75.
76.
AF Jorm H Christensen AS Henderson PA Jacomb AE Korten A Mackinnon 《Age and ageing》1996,25(2):126-129
Formal assessment of cognitive decline with cognitive tests can be difficult, requiring either two measurement points or a comparison of 'hold' with 'don't hold' tests. Informant-based assessment provides an alternative approach because informants can adopt a longitudinal perspective and directly rate cognitive change. A study was carried out to assess the validity of informant ratings collected by means of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). A community sample of 500 subjects aged 74 or over underwent four cognitive tests on two occasions 3½ years apart. On the second occasion, informants filled out the IQCODE. Subjects rated as having moderate or severe decline were found to have greater change on the cognitive tests. These findings support the validity of informant ratings of cognitive decline. 相似文献
77.
High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis 总被引:1,自引:0,他引:1
Shevchenko YL Novik AA Kuznetsov AN Afanasiev BV Lisukov IA Kozlov VA Rykavicin OA Ionova TI Melnichenko VY Fedorenko DA Kulagin AD Shamanski SV Ivanov RA Gorodokin G 《Experimental hematology》2008,36(8):922-928
High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic stem cell transplantation (auto-HSCT) is a new and promising approach to the treatment of multiple sclerosis (MS) patients because currently there are no effective treatment methods for this disease. In this article, we present results of a prospective clinical study of efficacy of HDIT + auto-HSCT in MS patients. The following treatment strategies were employed in the study: "early," "conventional," and "salvage/late" transplantation. Fifty patients with various types of MS were included in this study. No toxic deaths were reported among 50 MS patients; transplantation procedure was well-tolerated by the patients. The efficacy analysis was performed in 45 patients. Twenty-eight patients achieved an objective improvement of neurological symptoms, defined as at least 0.5-point decrease in the Expanded Disability Status Scale (EDSS) score as compared to the baseline and confirmed during 6 months, and 17 patients had disease stabilization (steady EDSS level as compared to the baseline and confirmed during 6 months). The progression-free survival at 6 years after HDIT + auto-HSCT was 72%. Magnetic resonance imaging data were available in 37 patients before transplantation showing disease activity in 43.3%. No active, new, or enlarging lesions were registered in patients without disease progression. In conclusion, HDIT + auto-HSCT suggests positive results in management of patients with different types of MS. Identification of treatment strategies based on the level of disability, namely "early," "conventional," and "salvage/late" transplantation, appears to be feasible to improve treatment outcomes. 相似文献
78.
In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease 总被引:10,自引:0,他引:10
Munro JM; Freedman AS; Aster JC; Gribben JG; Lee NC; Rhynhart KK; Banchereau J; Nadler LM 《Blood》1994,83(3):793-798
The B-lymphocyte/accessory-cell activation antigen B7 (BB1) has been shown in vitro to stimulate T-lymphocyte proliferation and cytokine production via CD28 present on the latter cells. In this study, benign lymphoid tissues, lymphomas, and extralymphoid inflammatory sites were examined immunohistochemically using anti-B7 and other relevant monoclonal antibodies. B7 was expressed by benign transformed germinal center B cells, as it was by B cells of follicular lymphomas. B7 was also expressed by a subpopulation (a mean of 31% to 65%) of macrophages and dendritic cells in a variety of lymphoid tissues. It was present in abundance on all macrophages constituting sarcoid granulomas in lymph nodes. In extralymphoid inflammation, 17% to 35% of macrophages expressed B7 only weakly. Cases of Hodgkin's disease showed expression of B7 by the majority of Reed-Sternberg cells or malignant mononuclear variants, a phenomenon that potentially contributes to the lymphocytic accumulation that is a feature of this condition. CD28+ T cells were seen in all areas where T cells were present. B7+ and CD28+ cells colocalized in, for example, lymphoid follicles, lymph node paracortex, sarcoid granulomas, and Hodgkin's disease tissue, indicating a potential for cellular interaction via these molecules at these sites. 相似文献
79.
Maciej Cabanski Brett Fields Stephanie Boue Natalia Boukharov Hector DeLeon Natalie Dror Marcel Geertz Emmanuel Guedj Anita Iskandar Ulrike Kogel Celine Merg Michael J. Peck Carine Poussin Walter K. Schlage Marja Talikka Nikolai V. Ivanov Julia Hoeng Manuel C. Peitsch 《Inflammation research》2015,64(7):471-486